Compare NPWR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NPWR | CRDF |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.9M | 187.9M |
| IPO Year | N/A | N/A |
| Metric | NPWR | CRDF |
|---|---|---|
| Price | $2.14 | $1.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.50 | ★ $10.83 |
| AVG Volume (30 Days) | 822.2K | ★ 1.8M |
| Earning Date | 03-09-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $501,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.86 | N/A |
| 52 Week Low | $1.48 | $1.48 |
| 52 Week High | $8.87 | $4.99 |
| Indicator | NPWR | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 31.74 | 27.95 |
| Support Level | $1.96 | $1.48 |
| Resistance Level | $2.43 | $1.76 |
| Average True Range (ATR) | 0.14 | 0.16 |
| MACD | -0.04 | -0.12 |
| Stochastic Oscillator | 12.12 | 2.55 |
NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. The company's business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. It has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.